Phaseline

Targets › CD74

CD74 (HLA class II histocompatibility antigen gamma chain): drug programs, companies and trials

2 programs from 2 companies in 6 trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.

Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF.; FUNCTION:…. (UniProt, P04233)

Open in Phaseline: the race on CD74, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbRepotrectinib
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 3Carcinoma, Non-Small-Cell LungFeb 2027
Turning Point TherapeuticsRepotrectinib (TPX-0005)
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 1Locally Advanced Solid Tumors; NSCLC; NSCLC Stage IV; Advanced CancerSep 2027

Conditions

Locally Advanced Solid Tumors (2) NSCLC (1) NSCLC Stage IV (1) Advanced Cancer (1) Carcinoma, Non-Small-Cell Lung (1)

Modalities

small molecule (2)

Companies

Turning Point Therapeutics (1) Bristol-Myers Squibb (1)

Related targets

NTRK1 (2) NTRK2 (2) ROS1 (2) NTRK3 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.